In this session, Sapient discusses application of its next-generation mass spectrometry approaches for large-scale biomarker discovery across diverse human diseases, enabling measure of tens of thousands of small molecule biomarkers across tens of thousands of individuals. See how integration of these biomarker studies with human genetics data is an approach for aligning the right patient, with their specific disease, and the optimal therapy to enhance drug efficacy and limit adverse events.